Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising

HB 484 modifies Maryland's corporate income tax code to disallow deductions for certain direct-to-consumer (DTC) pharmaceutical advertising expenses that are deductible under federal law. It specifically targets expenses paid by "covered entities" (pharmaceutical sponsors or companies owning drug outsourcing facilities) for advertising "covered drugs" (prescription drugs under federal law) to the general public via media like TV, radio, social media, or digital platforms. The bill requires these expenses - already deducted federally - to be added back to Maryland taxable income, effectively eliminating the state tax deduction for such advertising. This change applies to taxable years beginning after December 31, 2025, and directly affects pharmaceutical companies engaging in DTC advertising for covered drugs.